A subset of patients with metastatic castration-resistant prostate cancer who have low tumor mutational burden may benefit from checkpoint inhibition with ipilimumab if the tumor has a high density of CD8-positive T cells and increased interferon-interferon gamma signaling.
Shubham Pant, MD, discusses choosing therapy for the frontline and beyond in pancreatic cancer.
Matthew T. Campbell, MD, discusses the evolving treatment options in the renal cell carcinoma paradigm.
Ahmed O. Kaseb, MD, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses research with targeted therapy in hepatocellular carcinoma (HCC).
Kanwal Raghav, MBBS, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy and targeted therapy in colorectal cancer (CRC).
Michael J. Overman, MD, discusses factors to consider when choosing between regorafenib and TAS-102 in the third-line treatment of patients with colorectal cancer.
Douglas A. Nelson, MD, discusses results from the CheckMate-142 in metastatic colorectal cancer.
Jonathan Mizrahi, MD, discusses optimal sequencing in patients with BRAF V600E-mutant metastatic colorectal cancer.
Douglas A. Nelson, MD, discusses the quality-of-life data from the phase III BEACON CRC trial in metastatic colorectal cancer.
Phat Le, MD, discusses the need for aggressive therapeutic approaches in oligometastatic colorectal cancer.
Kanwal Raghav, MBBS, MD, discusses treatment options in newly diagnosed metastatic colorectal cancer.
Hun Ju Lee, MD, discusses the implications of phase I results regarding the combination of carfilzomib and ibrutinib in relapsed/refractory mantle cell lymphoma.
Jason Westin, MD, MS, FACP, discusses challenges with treating patients with large cell lymphoma.
Michael J. Overman, MD, discusses second-line therapy options for patients with colorectal cancer.
Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses known elements of COVID-19.
Jonathan Mizrahi, MD, discusses the goal of the phase III COMMIT trial in mismatch repair deficient colorectal cancer.
Phat Le, MD, assistant professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with oligometastatic colorectal cancer (CRC).
David S. Hong, MD, discusses the burgeoning role of multitargeted therapeutics in patients with hematologic malignancies.
Prithviraj Bose, MD, discusses the high unmet need in post-myeloproliferative neoplasms acute myeloid leukemia and the impact of findings from the phase I/II trial on current and future treatment strategies in the space.
Matthew T. Campbell, MD, MS, shares ways to prevent the spread of coronavirus 2019.
Jason Westin, MD, MS, FACP, discusses the role of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.
Neeta Somaiah, MD, discusses ongoing research in the field of sarcoma.
Ruben Mesa, MD, discusses the utility of fedratinib for patients with myelofibrosis who progress on first-line ruxolitinib.
Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR, discusses the findings of the retrospective analysis of pulmonary hypertension in patients with myelofibrosis and their impact on clinical practice.
Matthew H.G. Katz, MD, FACS, discusses the eligibility criteria for up-front surgery in patients with pancreatic cancer.
Shubham Pant, MD, discusses exciting data with PARP inhibitors in pancreatic cancer.
Jason Westin, MD, MS, FACP, discusses the potential for a chemotherapy-free future in large cell lymphoma.
Ryan W. Huey, MD, discusses potential sequencing options with sorafenib among novel combination strategies in hepatocellular carcinoma.
Combination therapy with cirmtuzumab and ibrutinib induced a 50% complete response rate in the phase I/II CIRLL study.
Robert L. Coleman, MD, FACOG, FACS, discusses the results of the phase III VELIA trial examining veliparib in combination with chemotherapy in ovarian cancer.
